---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-23-000038"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:30:59.055008+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Editas licenses Cas9 to Vertex for CASGEVY; receives $50M upfront, extends runway to 2026

## Summary
- Vertex gets non-exclusive Cas9 license for ex vivo BCL11A targeting sickle cell disease and beta thalassemia, including CASGEVY.
- Editas receives $50M upfront cash, $50M contingent upfront, and annual license fees of $10M-$40M through 2034.
- Editas must pay Broad Institute and Harvard a mid-double-digit percentage of amounts received from Vertex under the license.
- Cash runway extended into 2026, combining existing cash with upfront and near-term fees.

## SEC filing metadata
- accession: 0001650664-23-000038
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066423000038/0001650664-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066423000038/edit-20231212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-23-000038
- JSON: https://secwatch.observer/filing/0001650664-23-000038.json
- Plain text: https://secwatch.observer/filing/0001650664-23-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.